Login to Your Account


HCV regimen wins in Phase III; Street’s ‘ION’ Gilead pricing

By Randy Osborne
Staff Writer

Thursday, December 19, 2013

Ribavirin (RBV) could drop out of hepatitis C virus (HCV) therapy for genotype 1 (GT1) patients, as a result of Gilead Sciences Inc.’s triumph in the Phase III program known as ION, which tested the once-daily, fixed-dose combination of its approved nucleotide analog polymerase inhibitor Sovaldi (sofosbuvir) and the NS5A inhibitor ledipasvir, with and without RBV.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription